Biomolecular engineers at Rice identified a new Diels-Alderase (DAase), an enzyme that catalyzes the Diels-Alder reaction, a widely used method of synthesizing important materials and pharmaceuticals, from raw materials for plastics and fuels to synthetic steroids.
The enzyme, known as CtdP, was previously thought to be a different type of protein — a “regulator” controlling for gene expression. Regulators typically do not serve a catalytic function, meaning they cannot “transform compound A into compound B,” said study co-author Xue Sherry Gao.
The precision of CtdP’s catalytic activity is notable. Gao’s team was able to pinpoint a minute difference in a molecule’s spatial structure — or stereochemistry — as directly caused by the newly identified enzyme. “Only when our DAase is added do you get that very specific stereochemistry,” Gao said. “This is very important, because a subtle change in the stereochemistry of a small molecule can spell the difference between a drug and a poison.”
The study is published in Nature Chemistry.
First described by Kurt Alder and Otto Diels in 1928, the Diels-Alder reaction generated a wide range of industrial and pharmaceutical applications, earning the two German chemists the Nobel Prize in chemistry in 1950.
Gao explained that the Diels-Alder reaction is “very useful … because it can facilitate the formation of a wide range of cyclic ring structures” — characteristic features of many natural compounds that are medically useful. These bioactive natural products are found in microbes, plants and other organisms and can be used as drugs or as molecular blueprints for designing them.
Most Diels-Alder reactions, however, can be difficult to control with the precision required to achieve the desired 3D molecular structure. This is where the Gao lab’s CtdP discovery comes into play.
Knowing that a molecule’s stereochemistry can spell the difference between its behavior as a life-saving drug or as a lethal poison, Gao was curious how a fungal organism synthesized the 21R-citrinadin A molecule in only one of four possible configurations, or “stereochemical products.”
“Our question is, how does the living organism control the stereochemistry of this compound so precisely while achieving the same result through organic synthesis is so challenging?” she said.
CtdP turned out to be one of the answers. “Our enzyme ensures that the chemical reaction takes place with the desired stereochemical control,” she said.
Enzymes expedite or render a chemical reaction more efficient, but they typically do not determine whether a reaction will occur or not. What sets CtdP apart from other DAases is that it uses a unique mechanism to prime the substrate substance while simultaneously converting nicotinamide adenine dinucleotide phosphate, or NADP+, into its reduced form, or NADPH, which makes the Diels-Alder reaction possible in the first place, Gao said. “In sum, our study reveals a new class of DAases,” she said.
“Very few DAases work like our enzyme and very strictly synthesize a chemical reaction that is impossible without it,” she said. “We hope that our discovery will help develop biocatalysts that enable the production of useful pharmaceuticals in the near future.”
Gao and collaborators used computational analysis, in vivo and in vitro testing and X-ray crystallography to determine the molecular structure and mechanisms underlying CtdP’s catalytic activity.
Gao, the T.N. Law Assistant Professor of Chemical and Biomolecular Engineering and an assistant professor of bioengineering and chemistry, is a 2022 recipient of a prestigious CAREER Award from the National Science Foundation.
The National Institutes of Health (GM138207, GM11810, AI41481, GM122218, GM132046, GM116961), the Robert A. Welch Foundation (C-1952) and the University of Michigan supported the research. Computational resources were supported by the National Science Foundation via the UCLA Institute for Digital Research and Education, the San Diego Supercomputing Center through XSEDE (1548562) and D.E. Shaw Research.